home   /   news   /  Orient Gene has successfully developed the detection reagents for the differential diagnosis of COVID-19 mutant strains from the UK and South Africa
return
Orient Gene has successfully developed the detection reagents for the differential diagnosis of COVID-19 mutant strains from the UK and South Africa
2021-03-22

Orient Gene tracks the mutation of COVID-19 in a timely manner, and continues to accelerate the iteration of detection reagents to meet multiple detection needs. It has also successfully developed the nucleic acid detection kits for the differential diagnosis of COVID-19 mutant strains from the UK and South Africa, which are respectively the COVID-19 N501Y and HV69-70del gene mutation detection kit (fluorescence PCR method) and the COVID-19 K417N and E484K gene mutation detection kit (fluorescence PCR method), and will continue to be used in the international anti-epidemic front line.

 

In mid-December 2020, a new COVID-19 mutant strain B1.1.7 was published in the UK. At the end of December 2020, a new COVID-19 mutant strain emerged in the South Africa. After receiving the information, the company immediately carried out bioinformation analysis on the COVID-19 IgG/IgM antibody rapid test, COVID-19 antigen rapid test, and COVID-19 nucleic acid detection kits already on sale to verify whether the aforementioned COVID-19 mutant strains would be missed.

 

Meanwhile, the company has stepped up its R&D layout and recently successfully developed the following nucleic acid detection kits for the differential diagnosis of COVID-19 mutant strains from the UK and South Africa: 1. COVID-19 N501Y and HV69-70del gene mutation detection kit (fluorescence PCR method) for the differential diagnosis of B1.1.7 COVID-19 mutant strain in the UK, and the detection sites are two key mutations N501Y and HV69-70del; 2. COVID-19 K417N and E484K gene mutation detection kit (fluorescence PCR method) for the differential diagnosis of COVID-19 mutant strain in the South Africa, and the detection sites are two unique key mutations K417N and E484K. The above two newly developed detection kits have high mutation detection rate, simple operation, no need for calibration, simple and accurate judgment results, and the detection time is 40-55 minutes according to different instruments, which is suitable for most fluorescence PCR detectors on the market.

 

Since 2020, Orient Gene has leveraged 15 years of technological accumulation to give full play to its technological advantages, accelerate product iteration, and meet various detection needs. It has successively developed eight COVID-19 detection reagents, namely COVID-19 IgM/IgG antibody detection kit (colloidal gold method), COVID-19 nucleic acid detection kit (fluorescence PCR method), COVID-19 antigen rapid test paper (colloidal gold method), influenza A and B and COVID-19 antigen combined test paper (colloidal gold method), influenza A and B/COVID-19/respiratory syncytial virus/adenovirus antigen combined detection reagent, COVID-19 and influenza A and B nucleic acid detection kit (fluorescence PCR method), COVID-19 N501Y and HV69-70del gene mutation detection kit (fluorescence PCR method), and COVID-19 K417N and E484K gene mutation detection kit (fluorescence PCR method), and has become a global company with a complete range of COVID-19 epidemic detection reagents, leading technical indicators, and leading production capacity. Among which, the COVID-19 antibody and COVID-19 antigen detection reagents have been highly evaluated and recognized by customers in the international market, especially the COVID-19 antigen detection reagent in the second half of the year. Orient Gene has become one of the major suppliers of the international secondary epidemic.


亚洲色国产在线观看,亚洲国产精品高清在线,国内A级毛片免费观看,秋霞最新高清无码鲁丝片